939412-84-7

Basic information

• Product Name: N-((3-chloropyrazin-2-yl)Methyl)-3-oxocyclobutanecarboxaMide
• Synonyms: N-((3-chloropyrazin-2-yl)Methyl)-3-oxocyclobutanecarboxaMide
• CAS NO: 939412-84-7
• Molecular Formula: C10H10ClN3O2
• Molecular Weight: 239.6583
• EINECS: -0
• Mol File: 939412-84-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-((3-chloropyrazin-2-yl)Methyl)-3-oxocyclobutanecarboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((3-chloropyrazin-2-yl)Methyl)-3-oxocyclobutanecarboxaMide(939412-84-7)
• EPA Substance Registry System: N-((3-chloropyrazin-2-yl)Methyl)-3-oxocyclobutanecarboxaMide(939412-84-7)

Safety Data

• Hazardous Substances Data: 939412-84-7(Hazardous Substances Data)

Upstream product

• 939412-86-9 C-(3-chloropyrazin-2-yl)-methylamine hydrochloride salt 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 867165-53-5 (3-chloropyrazin-2-yl)methanamine bishydrochloride salt 
• 939412-81-4 3-oxocyclobutanecarboxylic acid 2,5-dioxopyrrolidin-1-yl ester 

Downstream Products

• 936901-72-3 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 
• 936901-73-4 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 

Relevant articles and documents

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS

The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.